Healthcare Tech Firm Finds Big U.S. Opportunity

1. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Onemednet Corp. (ONMD:NASDAQ) has entered into a multi-year agreement with Palantir Technologies Inc. (PLTR:NASDAQ) to support the development of OneMedNet's real-time AI-powered provider network, known as iRWD. The collaboration will integrate Palantir's Artificial Intelligence Platform (AIP) to manage and analyze vast amounts of clinical data across more than 1,750 provider sites. The integration is expected to enhance OneMedNet's ability to deliver anonymized, regulatory-grade data to organizations involved in life sciences, medical devices, and clinical research.

According to the companies, the partnership will allow users to access more than 5 billion administrative claims and over 131 million clinical exams. This dataset spans therapeutic areas such as oncology, cardiology, and rare diseases. Palantir's AIP platform is designed to streamline data discovery, improve delivery accuracy, and support compliance through integration with standards like SNOMED, ICD-10, and CPT. OneMedNet's proprietary anonymization algorithms will operate at scale on Palantir's infrastructure to ensure regulatory adherence and data protection.

"We're proud to provide the AI infrastructure for OneMedNet to accelerate the delivery of transformative healthcare solutions that will ultimately improve patient outcomes," said Drew Goldstein, Co-Head of Healthcare at Palantir, in a company statement. OneMedNet President and CEO Aaron Green noted that the partnership "helps us revolutionize our ability to deliver high-quality, regulatory-compliant data at remarkable speed."

The announcement comes as healthcare organizations continue to seek scalable AI solutions. Palantir has expanded its role in the healthcare sector in recent quarters, supporting various operational initiatives across government and commercial clients. According to its Q2 2025 update, Palantir reported adjusted free cash flow of US$569 million and a 57% margin, with U.S. commercial revenue increasing 93% year-over-year to US$306 million.

Understanding Healthcare Technology and Advanced Data Solutions

Healthcare technology has continued to reshape the medical landscape by streamlining operations, personalizing care, and improving access to real-time clinical data. According to the University of Central Florida, healthcare technology refers broadly to tools and systems that enhance medical delivery and patient outcomes, ranging from electronic health records and telemedicine platforms to machine learning algorithms and robotic surgery. These tools, the university explained, have allowed healthcare providers to implement "more precise diagnostics, personalized treatment plans and enhanced healthcare management."

The rapid pace of innovation has fueled a notable transition from traditional, paper-based systems to digital solutions capable of supporting large-scale data analytics. In a narrative review led by UCF's Varadraj P. Gurupur, researchers examined the growing role of artificial intelligence in areas such as health informatics, where AI supports "real-time decision-making and predictive health outcomes." Additionally, wearable devices and cloud-connected sensors have enabled continuous patient monitoring, empowering clinicians to intervene earlier in chronic disease management.

A report from Towards Healthcare, published October 6, highlighted that the advanced healthcare solutions market experienced robust growth, driven by "evolving patient expectations, rising demand for personalized care, and ongoing technological innovations." 

The market also saw a surge in remote patient monitoring and disease diagnosis applications. Towards Healthcare noted that these solutions "improve diagnostic accuracy, enable early detection of chronic conditions, and reduce human error in clinical decision-making." As a result, hospitals and clinics remained the leading end users of advanced healthcare solutions, with the sector's growth also fueled by strong government support for electronic records and precision medicine.

According to a report from MarketsandMarkets, the global artificial intelligence in healthcare market was valued at US$21.66 billion in 2025 and was projected to grow at a compound annual growth rate of 38.6%, reaching US$110.61 billion by 2030. The firm cited rising demand for early detection of chronic conditions and increasing adoption of AI tools in clinical decision-making as major growth drivers.

The AI Revolution Has Just Begun

According to Stephen McBride of RiskHedge, Palantir Technologies Inc. stood out as one of the top-performing AI-related stocks during the ongoing technology surge. Writing on September 3, he noted that Palantir had "jumped 160%" in recent months, alongside a broader rally in artificial intelligence equities. McBride viewed this growth not as speculative but as part of a foundational shift in the global economy, writing that "the AI market rally has substantial momentum remaining."

He emphasized that the industry appeared to be in an early-stage infrastructure buildout, drawing parallels to the 1990s internet era when investment in fiber optics and broadband laid the groundwork for later consumer-facing tech giants. "Today, the identical script is unfolding with AI, but on a grander scale," McBride wrote. He pointed to massive investments from both government and private entities as evidence of enduring sector strength, suggesting that companies aligned with this infrastructure and analytics trend, like Palantir, were positioned to benefit from unprecedented capital flows.

McBride highlighted U.S. government support through initiatives like the CHIPS Act and sovereign AI efforts, which were directing substantial funding toward AI development. He estimated that total AI infrastructure investment in the United States could eventually reach "up to US$1.8 trillion annually," roughly 6.3% of GDP, encompassing everything from data centers to grid upgrades.

He concluded that the biggest beneficiaries of this AI phase would be companies that use advanced platforms to enhance productivity and decision-making rather than those focused solely on infrastructure. "We want to own companies creating innovative new trains to leverage the AI era," he wrote, using a metaphor to distinguish between AI-enabling firms and infrastructure-heavy developers.

In an October 1 article, Joel South of Flywheel Publishing highlighted Palantir's recent momentum in both commercial and government sectors. He wrote that "Palantir has made several important announcements over the past few months, including its US$10 billion Army deal and a US$30 million contract with ICE," adding that these developments have helped drive short-term stock gains. South also noted the company's broader growth strategy, stating that Palantir's Artificial Intelligence Platform "empowers enterprises in healthcare, finance, and manufacturing to harness AI for data analytics."

TipRanks reports that "Based on 19 Wall Street analysts offering 12-month price targets for Palantir Technologies in the last 3 months. The average price target is US$156.53 with a high forecast of US$215.00 and a low forecast of US$45.00. The average price target represents a -14.73% change from the last price of US$183.56."

Leveraging AI Infrastructure to Expand Real-World Data Access

The partnership between OneMedNet and Palantir reflects a broader industry focus on real-world data (RWD) and artificial intelligence as enablers of innovation in life sciences and clinical research. By aligning OneMedNet's iRWD network with Palantir's AIP, the companies are creating a unified platform for rapid cohort generation, customized data delivery, and conversational search across large-scale clinical datasets.

Palantir's AI platform is designed to support healthcare clients with workflow automation and predictive analytics. For example, the company has demonstrated results such as reducing letter preparation time from 80 minutes to seven minutes and achieving over 1,000 flagged procedures to prevent downstream denials in hospital operations. These capabilities may become relevant to OneMedNet's customers as they navigate complex regulatory and research environments.

In Q2 2025, Palantir closed 157 commercial and government deals worth at least US$1 million, with U.S. commercial total contract value reaching a record US$843 million, a 222% increase from the prior year. The company's adjusted operating income rose to US$464 million with a 46% margin, contributing to a Rule of 40 score of 94%.

With healthcare data analytics projected to grow substantially in the coming years, OneMedNet's integration of Palantir's AI technology allows it to provide structured, real-time, and privacy-compliant data solutions to a wide range of stakeholders across the health sector. 

Ownership and Share Structure

According to Refinitiv, 3.6% of Palantir is held by management and insiders. .04% is owned by strategic entities.

55.79% is owned by institutions. Of those, the highest holders are Vanguard Group at 8.73%, BlackRock Institutional Trust Company with 5.83%, State Street Global Advisors with 3.91%, Geode Capital Management with 2.45%, and Invesco Capital Management at 2.06%.  The rest is retail. 

Palantir Technologies has a market cap of US$321.7 billion and a 52-week range of US$$38.78 - US$190.00.